

EU Authorisation Procedures

Instrument for Pre-Accession Assistance Programme (IPA) Introductory Meeting 1-2 February 2010

Presented by: Zaide Frias and Melanie Leivers Head of Section/Human and Veterinary Regulatory Affairs and Organisational Support

agency of the European Union




Background- The history of the EU system



1965: First Pharmaceutical Directive (65/65/EC)

triggered by Thalidomide catastrophe

EU law requires all medicinal products to obtain a Marketing Authorisation (MA) before they can be put on the EU market






European Commission - legislative tools




Regulation – binding to all Member State (MS), no national changes allowed e.g. Paediatric Regulation

Directive – result binding but transposition up to MS, local interpretation e.g. Clinical Trials Directive

Guidelines – "Soft Law", recommended but not binding e.g. "Guideline on the readability of the labelling and package leaflet of medicinal products for human use"







 Medicinal products have to be <u>authorised either</u> <u>at Member State or Community level</u> before they can be placed on the EU market

7 Instrument for Pre-Accession Assistance Programme (IPA)



EU Procedures

Legal Basis of a Marketing Authorisation for a medicinal product for human or for veterinary use

- Human Directive (<u>Directive 2001/83/EC</u>)
- Veterinary Directive (Directive 2001/82/EC)
- Regulation (EC) No 726/2004 (joint Regulation for products for human use and products for veterinary use)



Routes of authorisation

- National limited (one Member State)
- Mutual Recognition (Member States) authorisation granted first in one Member State and then recognised by the others

9 Instrument for Pre-Accession Assistance Programme (IPA)



EU Procedures

Routes of authorisation

- Decentralised (Member States) one application submitted in all Member States at the same time
- Centralised via the European Medicines Agency Scientific Opinions resulting in a European Commission Decision, applicable throughout the European Union (more about this in a later presentation)



Centralised Procedure

- Managed by single scientific committee (CVMP/CHMP)
- Generate binding scientific opinion
- Max. 210 days to Opinion
- Final Decision
 - 1 MA valid EU
 - 1 (invented) name
 - 1 common Product information
- 22 languages (+IS/NO)
- Transparent system (e.g. EPAR)
- 27 Member States
- Access to potentially 495 million
- 11 Instrument for Pre-Accession Assistance Programme (IPA)





EU Procedures

- Member State committee Co-ordination Group for Mutual Recognition and Decentralised Procedures – vet and human- (CMDv/CMDh)
- ❖ <u>agreement</u> on running of MR and DC procedures
- ❖ reach <u>agreement</u> on a product application



Referrals

- <u>Disagreements</u> between Member States sent ultimately to the European Medicines Agency for evaluation by scientific committee
- Can also be initiated in specific cases where the interests of the Community are involved
- May also concern a range of medicinal products or a therapeutic class

13 Instrument for Pre-Accession Assistance Programme (IPA)




EU Procedures

- Committee for Human/Veterinary Medicinal Products – CHMP/CVMP – for Centralised Procedure and referrals
- agreement on running of CP procedures
- reach <u>agreement</u> on referral procedures



Other procedures once a product is authorised:

- Extensions e.g. new pharmaceutical form, new food-producing target species
- Variations e.g. change to a product's shelf life
- Renewals 5 years after authorisation
- Transfers from one Marketing Authorisation Holder to another





Choice of EU procedure

Intended market size?

- National one market only
- Mutual Recognition/Decentralised free choice of MS markets within EU
- Centralised all EU MS markets in one go (incl. enlargement!)

Type of product?

- ➤ CP mandatory for biotech and advanced therapies products and orphan medicinal products and also for new active substances for: AIDS/HIV, Diabetes, Cancer, Neurodegenerative Disorders, Autoimmune diseases and dysfunctions, viral diseases
- MRP and DCP more for older substances and generics but open for all substances (as long as it is not covered by the mandatory CP list)
- 17 Instrument for Pre-Accession Assistance Programme (IPA)



Choice of EU procedure

Existing National MA?

- Mutual Recognition requirement
- Centralised/Decentralised product needs to be unlicensed

Trade/invented name?

- Single name in CP
- Different names possible in MRP/DCP

Price (fees)?

- CP expensive but includes all MS
- MRP/DCP fees needs to be paid to all involved MS
- 18 Instrument for Pre-Accession Assistance Programme (IPA)



Commission Communication The "Pharma Package" ...



Renewed vision on for the pharmaceutical sector

Legal proposals on:

- "Counterfeit" medicines
- "Information to patients"
- "Pharmacovigilance"

Five legal proposals amending
Directive 2001/83/EC and Regulation
(EC) No 726/2004

